Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
Yoon-Koo KangSuzanne GeorgeRobin L JonesPiotr RutkowskiLin ShenOlivier MirShreyaskumar PatelYongjian ZhouMargaret von MehrenPeter HohenbergerVictor M VillalobosMehdi BrahmiWilliam D TapJonathan C TrentMaria A PantaleoPatrick SchöffskiKevin HePaggy HewKate NewberryMaria RocheMichael C HeinrichSebastian BauerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Primary end point was not met. There was no significant difference in median PFS between avapritinib and regorafenib in patients with molecularly unselected, late-line GIST.
Keyphrases
- phase iii
- open label
- locally advanced
- squamous cell carcinoma
- clinical trial
- phase ii study
- phase ii
- rectal cancer
- neoadjuvant chemotherapy
- metastatic colorectal cancer
- double blind
- radiation therapy
- small cell lung cancer
- study protocol
- placebo controlled
- tyrosine kinase
- randomized controlled trial
- liver metastases